Liver Damage and Cardiometabolic Disorders in NAFLD
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-80
SponsorUniversity of Roma La Sapienza
About this trial
Liver fibrosis is the most important prognostic factor in patients with non-alcoholic factor disease. Clinical and biological condition, as diabetes or mutation for PNPLA3, are well known factors associated with liver fibrosis onset and progression. However, little is known about biochemical factors predicting liver fibrosis evolution in large NAFLD populations.
Eligibility criteria
Qualifiers
Patients aged 18 years old or more
Patients with at least on of the following metabolic disorders
Obesity
Diabetes
Disqualifiers
Average daily consumption of alcohol >20 g in women and of >30 g in men (assessed by Alcohol Use Disorders Identification Test, AUDIT;
presence of hepatitis B surface antigen and antibody to hepatitis C virus;
positive tests for autoimmune hepatitis;
cirrhosis and other chronic liver diseases;
Trial design
Treatments tested in this trial
- Not listed
Trial groups
No trial groups listed
Locations
1Day Service of Internal Medicine and Metabolic Disorders - Policlinico Umberto I - Sapienza University of Rome00100, Rome Italy
Sponsors and collaborators
University of Roma La Sapienza
Lead sponsor
Source ClinicalTrials.gov